96 Tests PN: B112515

Components:

45x Ab-conjugated beads (S4P4- Human NAP-2 Ab-bead). PN: B112515A. One vial containing 100 µL of anti-Human NAP-2 conjugated to AimPlex Bead S4P4.

25x Biotin-detection Ab (Human NAP-2 Biotin-dAb). PN: B112515B. One vial containing 100 µL of biotinylated anti-Human NAP-2.

Lyophilized Standard Mix-Human Group 7, Panel B, 7-Plex. PN: HG72006. One vial containing lyophilized recombinant NAP-2, PARC, sPD-1, PF4, SDF-1, TARC, and TECK.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human CXCL7/NAP-2. Can be multiplexed with other analytes in Human Group 7.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 10 pg/mL

  • Quantitation range:

  • LLOQ: < 20 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 7: Negligible

  • Sample volume: 15 µL/test

Description:

CXCL7 (Chemokine C-X-C motif ligand 7) also known as Neutrophile Activating Peptide-2 (NAP-2) and Small-Inducible Cytokine 7 (SCYB7), is a small cytokine belonging to the CXC chemokine family. It is an isoform of Beta-Thromboglobulin or Pro-Platelet basic protein.  CXCL7 is released in large amounts from platelets following their activation.  It stimulates various processes including mitogenesis, synthesis of extracellular matrix, glucose metabolism and synthesis of plasminogen activator. Diseases associated with PPBP include erythromelalgia and essential thrombocythemia.

References:

  1. Hristov M, Zernecke A, Bidzhekov K; et al. (March 2007). "Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury". Circ. Res. 100 (4): 590–7. doi:10.1161/01.RES.0000259043.42571.68. PMID 17272812.

  2. Majumdar S, Gonder D, Koutsis B, Poncz M (1991). "Characterization of the human beta-thromboglobulin gene. Comparison with the gene for platelet factor 4". J Biol Chem 266 (9): 5785–9. PMID 1826003.

  3. Castor C, Miller J, Walz D (1983). "Structural and biological characteristics of connective tissue activating peptide (CTAP-III), a major human platelet-derived growth factor". Proc Natl Acad Sci USA 80 (3): 765–9. doi:10.1073/pnas.80.3.765. PMC 393460. PMID 6572368.

  4. Castor C, Furlong A, Carter-Su C (1985). "Connective tissue activation: stimulation of glucose transport by connective tissue activating peptide III". Biochemistry 24 (7): 1762–7. doi:10.1021/bi00328a029. PMID 4005226.